Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

BioLineRx (BLRX) EBIT Margin (2023 - 2025)

Historic EBIT Margin for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to 516.86%.

  • BioLineRx's EBIT Margin fell 4078800.0% to 516.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 88.94%, marking a year-over-year increase of 1007400.0%. This contributed to the annual value of 70.52% for FY2024, which is 9647700.0% up from last year.
  • As of Q3 2025, BioLineRx's EBIT Margin stood at 516.86%, which was down 4078800.0% from 757.57% recorded in Q2 2025.
  • In the past 5 years, BioLineRx's EBIT Margin ranged from a high of 1405.71% in Q1 2023 and a low of 1816.63% during Q4 2023
  • For the 3-year period, BioLineRx's EBIT Margin averaged around 442.34%, with its median value being 312.92% (2024).
  • Examining YoY changes over the last 5 years, BioLineRx's EBIT Margin showed a top increase of 17789600bps in 2024 and a maximum decrease of -14760600bps in 2024.
  • Over the past 3 years, BioLineRx's EBIT Margin (Quarter) stood at 1816.63% in 2023, then skyrocketed by 98bps to 37.67% in 2024, then crashed by -1272bps to 516.86% in 2025.
  • Its last three reported values are 516.86% in Q3 2025, 757.57% for Q2 2025, and 937.65% during Q1 2025.